Study S000468

Treating PCOS With Semaglutide vs Active Lifestyle Intervention

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT03919929
Acronym: TEAL
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2; PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 60
Start: 2019-05-03
Primary completion: 2023-10-03
Lead sponsor: University of Colorado, Denver
Conditions: PCOS; Adolescent Obesity; NAFLD
Interventions: DRUG:Semaglutide 3mg and 7mg [Rybelsus]; OTHER:Weight loss diet
Results posted: TRUE
Individual participant data sharing: NO
Secondary identifiers: NIH:1R01DK120612-01A1

Registered primary outcomes

Change in Hepatic Fat Fraction [Baseline and 12 weeks]
Change in Weight [Baseline and 12 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0040528	From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis Manik Aggarwal, Clinical Liver Disease	2023	Other	PMID 36938314 DOI	cites ClinicalTrials.gov:NCT03919929